Examining Drug Industry Influence on Medical Education

By Rachel Walden |

We have written a fair bit here in the past about direct-to-consumer drug advertising and drug industry payments to physicians, but a recent New York Times article points to another area in which drug industry dollars may have an unexpected influence – medical education.

The article offers this example:

In a first-year pharmacology class at Harvard Medical School, Matt Zerden grew wary as the professor promoted the benefits of cholesterol drugs and seemed to belittle a student who asked about side effects.

Mr. Zerden later discovered something by searching online that he began sharing with his classmates. The professor was not only a full-time member of the Harvard Medical faculty, but a paid consultant to 10 drug companies, including five makers of cholesterol treatments.

Zerden wasn’t the only concerned Harvard medical student – more than 200 of them, along with some faculty, are apparently riled up and working to expose these types of connections and payments. From other students:

“Harvard needs to live up to its name,” said Kirsten Austad, 24, a first-year Harvard Medical student who is one of the movement’s leaders. “We are really being indoctrinated into a field of medicine that is becoming more and more commercialized.”

David Tian, 24, a first-year Harvard Medical student, said: “Before coming here, I had no idea how much influence companies had on medical education. And it’s something that’s purposely meant to be under the table, providing information under the guise of education when that information is also presented for marketing purposes.”

Students such as these are also alarmed that Harvard Medical School received an “F” grade on the American Medical Students Association’s 2008 PharmaFree Scorecard, a rating of conflict of interest policies at academic medical centers in the United States.

The students’ efforts have apparently generated results, such that there is now “a requirement that all professors and lecturers disclose their industry ties in class — a blanket policy that has been adopted by no other leading medical school.” A committee has also been established to re-examine the institution’s conflict-of-interest policies, and includes student members.

Relatedly, the Times also reports that last fall a Pfizer employee turned up on Harvard’s campus to photograph students who were protesting pharmaceutical industry influence on campus.

The AMSA scorecard mentioned in the article is freely accessible online, allowing users to browse and compare institutions and view policy information on gifts and samples, disclosure, site access, curriculum, and other factors.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

One Comment

  1. George C.Paul says:

    I am really happy that the fact of drug industry influence on medical education,is at last getting the right attention from the right section of society

    ( Medical students).But what about spreading this movement to countries like India, China,Brazil & Russia ?

    I am from India, I have been increasingly feeling uneasy about the close connection developing between Doctors and drug companies in India.Of late i have felt that the CME programs at many locations, especially close to medical schools are becoming too closely linked to Drug industry marketing departments. The awareness of side effects being suppressed in case of Cholesterol lowering drugs is a classic example.The business cycle of Drug-Side effect- Crisis- hospitalization- New treatment with still more drugs for various symptoms those pass off as developments related to falling health of an aging person, is in full swing,in urban India.